RGRXRegeneRx Biopharmaceuticals, Inc.

About RegeneRx Biopharmaceuticals, Inc. (RGRX)

RegeneRx Biopharmaceuticals, Inc. (RGRX) is a Biotechnology company headquartered in Rockville, MD, United States whose shares trade over-the-counter on the Expert Market tier.

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx's mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.

Products and services

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications

RGRX key facts

Ticker symbol

RGRX

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Rockville, MD, United States

Country of incorporation

US

Year of incorporation

1982

Employees

3

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Audited

Fiscal year end

12/31

RegeneRx Biopharmaceuticals, Inc. leadership

• J.J. Finkelstein — President, CEO
• Dane Saglio — CFO
• Lori Herman — Administrator

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with R